|
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer
RECRUITINGPhase 2Sponsored by Fudan University
Actively Recruiting
PhasePhase 2
SponsorFudan University
Started2026-09-14
Est. completion2027-12-31
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07841236
Summary
This prospective, multicenter, single-arm phase II interventional study evaluates whether longitudinal circulating tumor DNA (ctDNA) monitoring can guide neoadjuvant immunotherapy and surgical decision-making in dMMR/MSI-H colon cancer. Participants with ctDNA clearance proceed to curative surgery, whereas those with persistent ctDNA positivity escalate to combined PD-1 and CTLA-4 inhibitor therapy.
Eligibility
Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria: * Written informed consent obtained before any study-related procedures. * Age 18 to 75 years, inclusive. * Histologically confirmed colon adenocarcinoma, mucinous adenocarcinoma, or signet-ring cell carcinoma, with the tumor located at least 15 cm from the anal verge. * dMMR/MSI-H status confirmed by immunohistochemistry, polymerase chain reaction, or next-generation sequencing. * Eastern Cooperative Oncology Group performance status of 0 or 1 and an expected survival of at least 3 months. * Adequate hematologic, hepatic, renal, coagulation, thyroid, and cardiac function, as defined in the protocol. * Negative pregnancy test for women of childbearing potential; agreement to use highly effective contraception, when applicable. Exclusion Criteria: * Prior treatment with a PD-1 inhibitor, CTLA-4 inhibitor, or other immunotherapy. * Symptomatic or high-risk bowel obstruction, bleeding, perforation, pneumonitis, or other conditions that may compromise safe study participation. * Another malignancy diagnosed within 5 years before the first study treatment, except for specified definitively treated low-risk malignancies. * Current participation in another interventional clinical study, or receipt of another investigational drug or investigational device within 4 weeks before the first study treatment. * Active autoimmune disease requiring systemic treatment within 2 years before the first study treatment, or recent systemic corticosteroid or other immunosuppressive therapy. * Uncontrolled pleural effusion or ascites, prior allogeneic organ transplantation (except corneal transplantation), or allogeneic hematopoietic stem cell transplantation. * Known hypersensitivity to any study drug component. * Toxicities or complications from prior treatment not recovered to Grade 1 or baseline, except for specified conditions. * HIV infection, untreated active hepatitis B infection, or active hepatitis C infection. * Receipt of a live vaccine within 30 days before the first study treatment. * Pregnancy or breastfeeding. * Any serious or uncontrolled systemic disease, active infection, clinically significant laboratory abnormality, or other condition that may interfere with study participation or place the participant at unacceptable risk, as judged by the investigator.
Conditions4
CancerColon CancerDeficient Mismatch RepairMicrosatellite Instability-high (MSI-H)
Interventions2
Related trials
- A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma) — Sun Yat-sen University
- An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment — Xinqiao Hospital of Chongqing
- CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer — Fudan University
- CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC — Fudan University
- Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer — Ruijin Hospital
- Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors — Ruijin Hospital
- Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer — Jinbo Yue
- First in Human Study of YB1-X7 Injection — Shanghai Salvectors Biotechnology LTD.
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorFudan University
Started2026-09-14
Est. completion2027-12-31
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07841236